The overarching aim of this study is to develop new, sensitive measures for aspects of social cognition (emotion experience, empathy and affective theory of mind), that will contribute to a better and earlier diagnosis of specific subtypes (theā¦
ID
Source
Brief title
Condition
- Neurological disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameter is sensitivity of the new SC tests, assessed by SC
performance of patients with bvYOD compared to healthy controls. Subsequently,
we will investigate construct validity of the new measurements by relating it
to other social cognitive and other cognitive measures.
Secondary outcome
In a subset of the participants assessed for the main study parameters,
complemented by a group of non behavioural YOD and frontal brain injury
patients, the ecological validity of the new SC tests will be exploratorily
investigated by assessing the relationship between the SC tests and measures of
risk-taking behaviour.
Background summary
Young-onset Dementia (YOD) refers to dementia with the onset before the age of
65 years. A common type of YOD is frontotemporal dementia (FTD), but there can
also be young onset subtypes of Alzheimer*s disease, as well as many other
different subtypes. Characteristic of YOD is that impairments in language,
perception or (social) behavioural changes are usually more prominent in the
early disease stages than memory impairments, which are the hallmark of late
onset dementia, in particular Alzheimer*s disease. These non-memory symptoms
are often under-recognized, which delays the diagnosis of YOD and consequently
contributes to a much more difficult situation for both patients and their
close others. An important affected domain in various subtypes of YOD, is
social cognition (SC). SC refers to the capacities that enable adequate social
behaviours and interactions and includes aspects such recognition of other
person*s emotional expressions, the ability to experience emotions, empathy and
perspective-taking or theory of mind (ToM). SC is underpinned by
frontal-subcortical networks, which are affected in specific subtypes of YOD,
in particular in frontotemporal dementia and behavioural variant of Alzheimer*s
disease. Similar, impairments in social cognition are also found in patients
with other neurological disorders that mainly affect frontal-subcortical
networks, such as severe traumatic brain injury (TBI) or frontally located
brain tumours.
A major characteristic of impaired SC is emotional flattening. Patients
experience no or less (bodily feelings of) emotions. Being able to feel one*s
own emotions is a prerequisite for emotional empathy, since the ability to
empathize with others involves sharing feelings. Such an inability to detect
emotional signals, for instance feelings of fear, that indicate danger during
decision-making, or to take other people*s feelings and perspective into
account is likely to result in inadequate, inappropriate or even problematic
social behaviour, so called *behaviours of concern*, which are potentially
harmful to other people, such as aggression or unsafe driving.
At present there are only a few neuropsychological tests available that measure
aspects of SC. Even more so, tests that reliably measure the abilities to feel
emotions, to have empathy with others and to take others* emotions and
perspective into account in situations involving the safety of other people,
are still lacking. Hence, there is a large unmet need for better
neuropsychological measures of social cognition that are sensitive to these
impairments in emotional feelings and empathy (indicating possible risk of
behaviours of concern). Having such measures available will also likely allow a
more timely diagnosis of the specific behavioural subtypes of YOD.
Study objective
The overarching aim of this study is to develop new, sensitive measures for
aspects of social cognition (emotion experience, empathy and affective theory
of mind), that will contribute to a better and earlier diagnosis of specific
subtypes (the behavioural variants, bv) of YOD. To this end, the first step is
to assess the sensitivity of the newly developed measures for these aspects of
social cognition, by comparing the performance of patients with a bvYOD
diagnosis to the performance of healthy controls. In addition, construct
validity will be investigated by relating performance on the new SC tests to
existing social cognitive tests (convergent validity) and other general,
non-social cognitive tests measuring for example memory, information processing
speed and attention (divergent validity).
In a second, smaller sub-study, it will be explored whether the new tests are
also ecologically valid, that is, are related to unsafe, risk-taking behaviour
in real life situations. To this end, we will make use of driving simulator
scenarios created to elicit risk-taking behaviour, and to simulate a real world
environment, without the unwanted possibility of eliciting risk-taking
dangerous behaviours in real world situations. The aim of this sub-study is to
investigate whether impaired performance on the new SC tests is related to
risk-taking behaviour. First, this will be analysed in patients already
diagnosed with bvYOD, but also in other patients with frontal damage, to
investigate whether this relation is generic (with the future purpose that the
tests may be broader applicable in the future than only for the diagnosis of
YOD). Second, to investigate whether this relationship is specific, patients
with non-bvYOD variants will be included in the analyses, for whom no SC
impairments or risk-taking behaviour are expected.
Study design
This study is designed as an observational and experimental case-control study.
Study burden and risks
There are no direct benefits for the patient. A potential risk is simulator
sickness (similar to car sickness) during the driving simulator test.
Participants are notified of this possibility beforehand and will be monitored
during the test. They will also be informed of their right to stop the test at
any time. A general risk is that assessments (neuropsychological assessment and
driving simulator assessment) can be too demanding for patients; however,
neuropsychologists carrying out the assessments are experienced in testing
vulnerable patients and will carefully monitor whether the assessments are too
demanding, and quit if necessary.
Hanzeplein 1
Groningen 9713GZ
NL
Hanzeplein 1
Groningen 9713GZ
NL
Listed location countries
Age
Inclusion criteria
Main study
All subjects
- Sufficient command of the Dutch language
- Age 18 to 70
bvYOD subjects
- Probable diagnosis of young-onset (before 65 years old) bvFTD according to
the current criteria (Rascovsky et al., 2011) or bvAD according to criteria
current criteria (McKhann et al., 2011), or another behavioural YOD subtype,
confirmed after interdisciplinary consensus meeting in which interviews,
neuropsychological examination, neurological and psychiatric assessments,
neuro-imaging, blood samples, and in some cases FDG/PIB-PETscans, CSF
biomarkers or genetic counselling were discussed.
Additional criteria for additional Risk-taking assessment
All subjects
- Any recent (<5 years) driving experience
Non-bvYOD subjects
- Probable diagnosis of young-onset dementia (before 65 years old) other than a
behavioural YOD subtype such as bvFTD or bvAD, for example amnestic variant AD,
confirmed after interdisciplinary consensus meeting in which interviews,
neuropsychological examination, neurological and psychiatric assessments,
neuro-imaging, blood samples, and in some cases FDG/PIB-PETscans, CSF
biomarkers or genetic counselling were discussed.
Frontal brain injury subjects
- Patients with frontal brain injury (e.g. traumatic brain injury, stroke or
brain tumour patients).
Non-frontal brain injury subjects
- Patients with non-frontal brain injury (e.g. traumatic brain injury, stroke
or brain tumour patients).
Exclusion criteria
YOD subjects:
- Presence of premorbid severe neurological or psychiatric pathology,
non-related to dementia.
Brain injury subjects:
- Presence of serious psychiatric disorders or other neurological comorbidities.
Healthy control subjects:
- Presence of serious psychiatric disorders
- History of neurological disorders, which may interfere with cognitive
functioning (e.g. recent concussion, previous subarachnoid or intracerebral
haemorrhage, intracranial tumours, epilepsy, ischemic stroke).
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT06286293 |
CCMO | NL87574.042.24 |